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Insulin autoimmune syndrome, characterized by the presence of insulin-binding autoantibodies and fasting or late
postprandial hypoglycemia, is a rare cause of hypoglycemia. We report a patient with pulmonary tuberculosis who
developed recurrent spontaneously post-absorptive hyperinsulinemic hypoglycemia after treatment with anti-
tuberculous drugs. Imaging studies of the pancreas were unremarkable, and selective intra-arterial calcium stimulation
with hepatic venous sampling for insulin failed to show a gradient, thus almost completely excluding the possibility
of occult insulinoma or nesidioblastosis. Examinations of sera, however, disclosed a high titer of polyclonal insulin-
binding autoantibodies containing at least 2 classes of binding sites, 1 with high affinity but low capacity, and the
other with low affinity but high capacity. An oral glucose tolerance test revealed high serum levels of total insulin
associated with relatively low levels of free insulin, but not of C-peptide, suggesting binding of the released insulin
to autoantibodies. Regretfully, shortly after the withdrawal of isoniazid, the patient died of respiratory failure unrelated
to hypoglycemia, and whether these antibodies were induced by isoniazid remains unknown. We recommend that
insulin autoimmune syndrome be one of the differential diagnoses in patients with hyperinsulinemic hypoglycemia.
[J Chin Med Assoc 2005;68(2):82–86]
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Introduction
Hypoglycemia with concurrent hyperinsulinemia im-
plies exogenous or endogenous insulin action related
either to medications or pancreatic lesions. Prolonged
fasting, the gold standard test for hypoglycemia, helps
to confirm the presence of inappropriate insulin secre-
tion from insulinoma or diffuse islet-cell hyperplasia
(nesidioblastosis). Insulinoma, if present, may be
localized by imaging studies, whereas a negative result
does not completely exclude the possibility of occult
islet-cell tumor or nesidioblastosis, in which insulin
secretion can be triggered by calcium injection into the
arteries supplying the tumor or the nesidiodysplastic
tissue, a technique termed “selective intra-arterial
calcium stimulation” testing or “arterial stimulation
and venous sampling (ASVS)”.1 The detection rate of
insulinoma with this localization method was reported
to be about 85–90%.1 However, spontaneous hyperin-
sulinemic hypoglycemia can be due to a much rarer
disorder, insulin autoimmune syndrome (IAS),2–6 which
is characterized by hypoglycemia, a high concentration
of total serum immunoreactive insulin (IRI), and
circulating monoclonal or polyclonal insulin-binding
autoantibodies. Mostly, IAS patients have either an
underlying autoimmune disorder or have previously
been exposed to drugs containing a sulfhydryl group,
such as methimazole. Herein is a case of recurrent
severe hypoglycemic coma caused by IAS after anti-
tuberculous drug therapy.
Case Report
A 76-year-old man was admitted to our hospital with
recurrent severe hypoglycemic coma. His past history
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included a case of chronic bronchitis, but no diabetes
mellitus or treatment with insulin or oral antidiabetic
drugs. Three months before admission, the patient
had developed poor appetite and weight loss of ap-
proximately 10 kg within a few months. A chest X-ray
taken at a local hospital disclosed ill-defined opacities
in both lung fields, with more dense infiltration over
the right upper lobe and bilateral basal lung regions.
Pulmonary tuberculosis was proven by a positive acid-
fast stain on sputum specimen. Anti-tuberculous
therapy with ethambutol 400 mg twice daily and
Rifater® 2 tablets twice daily (each tablet contains
rifampicin 120 mg, isoniazid 80 mg and pyrazinamide
250 mg) was started. One month after taking anti-
tuberculous drugs, a sudden onset of cold sweating,
palpitations and loss of consciousness occurred; symp-
toms were relieved after intravenous glucose injection.
Then, the patient was admitted to the local hospital
again. During the hospitalization, several episodes of
disturbed consciousness recurred and the diagnosis of
hyperinsulinemic hypoglycemia was made. During
1 episode of disturbed consciousness, the following
values were recorded: serum glucose concentration
19 mg/dL; insulin (IRI) 45.7 +IU/mL; and C-
peptide 0.96 ng/mL. Magnetic resonance imaging of
the abdomen was negative. The patient was transferred
to our hospital for further evaluation.
Clinically, the patient had clear consciousness but
looked chronically ill and cachectic, with a body weight
of 35.3 kg. Physical examination disclosed coarse
breath sounds and marked muscle wasting. Blood cell
counts and biochemical data were unremarkable, except
for hyponatremia (121 mmol/L), hypoalbuminemia
(2.9 g/dL), and hyperglobulinemia (5.0 g/dL). The
patient was euthyroid with a thyroid-stimulating
hormone level of 2.99 +IU/mL (normal range, 0.4–
4.0 +IU/mL) and free thyroxine level of 1.28 ng/dL
(normal range, 0.8–1.9 ng/dL). Anti-thyroglobulin
and anti-peroxidase antibody levels were 21 U/mL
(normal range, < 60 U/mL) and 328.5 U/mL (normal
range, < 60 U/mL), respectively.
Prolonged fasting was not performed, since an
episode of hypoglycemia occurred again soon after
admission. During this episode, a plasma glucose
concentration of 35 mg/dL and simultaneous
IRI level of 27.22 +IU/mL and C-peptide level of
3.22 ng/mL were noted. These findings were consis-
tent with hyperinsulinemic hypoglycemia. The 8 a.m.
serum cortisol level was 14.32 +g/dL, which rose to
19.99 +g/dL after a low-dose (5 +g) adrenocortico-
tropin-stimulation test, thus excluding the possibility
of adrenal insufficiency. Imaging studies, including
abdominal computerized tomographic scan and
pancreatic angiography, failed to detect lesions. An
ASVS test, as previously described by Doppman,1 was
performed for possible occult pancreatic abnormali-
ties. Briefly, after standard pancreatic angiography,
calcium was infused into different arteries via a catheter
inserted through the femoral artery, and blood samples
were withdrawn from the right hepatic vein for insulin
determination. The results revealed no gradient of
insulin level after calcium injection into the superior
mesentery artery, the gastroduodenal artery, the hepatic
artery, the proximal splenic artery, or the distal splenic
artery. These findings almost certainly excluded the
possibility of occult insulinoma or nesidioblastosis.7
Plasma-protein electrophoresis revealed a low
albumin level and a wide-base elevation of polyclonal
gamma globulin. Plasma immunoglobulin (Ig)
fractions of IgG, IgA and IgM were 2,380 mg/dL
(normal range, 751–1,560 mg/dL), 673 mg/dL
(normal range, 82–453 mg/dL), and 73.1 mg/dL
(normal range, 46–304 mg/dL), respectively. In
addition, an unusually high level of insulin auto-
antibodies (up to 86%; normal, < 5%) was identified in
the patient’s serum, and we assumed that these insulin-
binding autoantibodies belonged to the IgG class.
To further characterize the endogenous insulin-
binding activity of these autoantibodies, we compared
sera from a normal subject and from the patient,
before and after 50% ammonium sulfate precipitation,
with a method described by Redmon et al.8 Briefly,
normal serum, an aliquot of patient’s serum, and
re-dissolved ammonium sulfate precipitant, were
incubated with 125I-labeled insulin for 24 hours at
4$C; the bound fraction was then precipitated with
polyethylene glycol. As shown in Table 1, most of the
binding activity was retained in the fraction precipitated
by ammonium sulfate; this confirmed the presence of
insulin-binding Ig in the patient’s serum.
The binding characteristics of insulin autoanti-
bodies were further analyzed using an equilibrium-
Table 1. Endogenous insulin-binding activity determined
before and after ammonium sulfate precipitation
Serum
Bound insulin (%)
Before precipitation After precipitation
Normal subject < 3 < 3
Patient 80 49
Serum samples from a control subject and the patient, obtained before
and after precipitation with 50% ammonium sulfate, were incubated
with 125I-labeled insulin for 24 hours at 4ºC. After polyethylene glycol
precipitation, the radioactivity of protein-bound 125I-labeled insulin was
measured. More than 60% of bound insulin was retained in the precipitate
of ammonium sulfate.
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binding assay described by Goldman et al.9 First, de-
insulinization of the patient’s serum was performed by
acidification and absorption with dextran-coated
charcoal. Then, the serum at a final dilution of 1:5 was
incubated for 2 hours at 37$C with 125I-insulin and
increasing concentrations of cold insulin. A Scatchard
plot of the binding data was then constructed (Figure
1), in which a curvilinear pattern was evident, indicating
heterogeneity of the binding sites. Two classes of
binding sites were identified: 1 had an affinity
constant of 1 = 1010 L/mol and binding capacity of
2.64 = 10–9 mol/L (high affinity/low capacity); the
other had an affinity constant of 1 = 108 L/mol and
binding capacity of 9.6 = 10–6 mol/L (low affinity/
high capacity), suggesting a polyclonal nature of the
autoantibodies.
Capillary blood glucose concentrations were
monitored every 2 hours to study the pattern of hypo-
glycemia in the patient. A 24-hour blood glucose
profile revealed post-absorptive hypoglycemia, with a
nadir occurring about 3–4 hours after a meal (Figure
2). Both IRI and C-peptide concentrations obtained
during hypoglycemia were elevated.
To further define the relationship between the
serum concentrations of free insulin, the biologically
active fraction of insulin, total insulin, and C-peptide
levels, a 5-hour oral glucose tolerance test was
performed. After a 100 g glucose load, total insulin
level increased markedly at 30 minutes, and declined
slowly thereafter, remaining elevated above baseline
until 5 hours; free insulin showed only a slight increase.
C-peptide level was also raised at 30 minutes, but
began to decline at 2 hours (Figure 3), suggesting a
delay in the clearance of insulin.
As isoniazid has previously been associated with
hypoglycemia and insulin autoantibodies, it was
discontinued. Unfortunately, this patient eventually
died from respiratory failure. Permission for autopsy
was refused by the family.
Discussion
IAS, first described by Hirata et al in the 1970s, is an
extremely rare disorder.2 To date, approximately 200
cases have been reported, and more than 90% of them
were in Japanese patients,5,6 in whom an underlying
autoimmune disease or an exposure history to a sulfhy-
dryl drug, such as methimazole, had been found.2–6
Figure 1. The ratio of bound to free insulin (B/F) for different
concentrations of bound insulin (Scatchard plot). Two classes of
binding sites were identified: 1 had an affinity constant of 1 =
1010 L/mol and binding capacity of 2.64 = 10–9 mol/L (high affinity/
low capacity); the other had an affinity constant of 1 = 108 L/mol
and binding capacity of 9.6 = 10–6 mol/L (low affinity/high capacity).
Figure 2. A 24-hour blood glucose profile revealed postprandial
hypoglycemia. Black arrows indicate the mealtimes.
Figure 3. After a 100 g glucose load, total insulin increased
markedly, whereas free insulin showed only a slight increase. The
level of total insulin remained high until 5 hours, indicating a
relatively delayed clearance relative to C-peptide, which began to
decline at 3 hours. Glucose (●), free insulin (▲), total insulin (▲),
C-peptide (◆).
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Typically, the hypoglycemic episodes arose during the
late postprandial period, and it was assumed that insu-
lin secreted immediately after a meal was bound to
autoantibodies and then dissolved from the complex
to exert its effect, thus producing postprandial hypo-
glycemia.9,10 However, IAS can present with fasting or
post-absorptive hypoglycemia. In this situation, it is
difficult to differentiate IAS from hyperinsulinemic
hypoglycemia due to insulinoma or islet-cell hyper-
plasia, although IRI level could be a diagnostic clue,
since in patients with IAS, the measured insulin level
is usually high (sometimes > 1,000 +IU/mL) because
of the high capacity of insulin-binding autoanti-
bodies.2,10–12 However, depending on the insulin anti-
body used and the method employed for the insulin
assay, IRI level may be only mildly or moderately
elevated.5,12 The insulin level (27.22 +IU/mL) of our
patient during a hypoglycemic episode was determined
by a specific chemiluminescent immunoassay (ADVIA
Centaur insulin assay, Bayer Corporation, Tarrytown,
NY, USA), which has no cross-reactivity with either
proinsulin or C-peptide, rather than by conventional
radioimmunoassay; this might explain the low insulin
level observed. The method used to determine insulin
level (45.7 +IU/mL) during a hypoglycemic episode
at the other hospital was unknown.
Redmon et al reported a similar case in which the
patient developed postprandial hypoglycemia due to
monoclonal insulin-binding antibodies produced by
multiple myeloma.8 In our patient, the markedly
elevated levels of total insulin and C-peptide, but
much lower level of free insulin, together with the fact
that total insulin, unlike C-peptide, remained elevated
while plasma glucose began to decline during an oral
glucose tolerance test, suggest a delayed clearance of
insulin, apparently due to binding of released insulin
by insulin-binding autoantibodies. These observations,
consistent with the findings of Hirata and Uchigata6
and Redmon et al,8 support the notion that the
insulin-autoantibody complex is responsible for the
development of late postprandial hypoglycemia in
patients with IAS.
The binding characteristics of insulin autoantibod-
ies in this case were polyclonal and carried at least 2
classes of binding sites with different affinities and
binding capacities, as demonstrated on the Scatchard
plot. In agreement with previous observations in most
patients with drug-induced IAS,2,10–12 and in insulin-
treated diabetic patients,9 1 class of the autoantibody
had a high affinity but relatively low binding capacity,
whereas the other had a high binding capacity but low
affinity. The kinetic characteristics of these insulin-
binding autoantibodies, however, were different from
those induced by monoclonal gammopathy, in which
a single class of binding site alone was found on the
Scatchard plot.8,13
The cause of IAS is heterogeneous and remains
incompletely understood. Underlying autoimmune
disorders, specific human leukocyte antigen (HLA)
typing, structural abnormalities of insulin, sulfhydryl-
containing drugs such as methimazole (most common),
thiopronin, penicillamine, glutathione, and other
drugs, including hydralazine, procainamide and
isoniazid, have been associated with this uncommon
syndrome.2,5,6,12,14,15 Rarely, IAS may result from
monoclonal insulin-binding autoantibodies produced
by multiple myeloma or benign monoclonal gam-
mopathy.7,13 Immunogenetic evidence suggests a
striking association between polyclonal IAS and
specific HLA class II antigens such as DRB1*0406,
DQA1*0301 and DQB1*0302.12 Further studies
indicate that certain amino acids at position 74 in the
HLA-DR4 `1 chain might be involved in the patho-
genesis of insulin autoantibody production.12 Unfor-
tunately, lack of HLA typing data limited genetic
studies in our patient.
Villaume et al reported a woman treated with
isoniazid who developed hyperinsulinemic hypogly-
cemia with a normal C-peptide level.14 In that article,
the authors eliminated the possibility of IAS according
to the results of a gel filtration-elution profile, in which
the fraction of high molecular weight IRI was not
elevated; in addition, insulin-binding antibodies were
absent 18 months later. However, insulin-binding
antibodies could have been transiently present in the
serum.5 Also, the high total IRI concentration found
in the patient is a typical feature of IAS.2–6 Thus, the
possibility of “isoniazid-induced IAS” could not be
excluded completely. Furthermore, Trenn et al reported
a patient who received anti-tuberculous drugs and
developed IAS several years later; however, further
discussion was not provided.15 In the summaries of
IAS by Burch et al5 and Hirata and Uchigata,6 isonia-
zid was included as one of the causes of drug-induced
IAS. Unfortunately, all the above reports provide
neither enough evidence for an association between
isoniazid and IAS, nor the possible mechanisms of IAS
pathogenesis.
Our patient had taken isoniazid for pulmonary
tuberculosis for nearly 1 month before the first hypo-
glycemic attack. There was no exposure history for
insulin or insulin-stimulating drug therapy, and
insulinoma/nesidioblastosis were almost completely
excluded by imaging and ASVS studies. No underlying
autoimmune disorders or other causes of IAS could be
traced. Therefore, IAS induced by isoniazid was the
W.Y. Ma, et al
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most likely cause of hypoglycemia, but remained
unproven due to the short clinical course.
In conclusion, IAS, although uncommon clinically,
should be one of the differential diagnoses in patients
with hyperinsulinemic hypoglycemia, especially in
patients receiving isoniazid therapy.
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